A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Trial details
- Registry ID
- NCT07902817
- Drugs studied
- JADE101
TrialRedline tracks 2 clinical trials sponsored by Jade Biosciences, Inc.: 1 Phase 3, 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyNCT07902817 | JADE101 | Recruiting | 2029-06Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of JADE101 in Participants With Immunoglobulin A NephropathyNCT07541287 | JADE101 | Recruiting | 2029-01Estimated |
Names as written in the registry records.
NCT07902817 · Jade Biosciences, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT07541287 · Jade Biosciences, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety and tolerability of JADE101 in participants with IgA nephropathy. After: Measure: Incidence of treatment-emergent adverse events (safety and tolerability).
Before: Not yet recruiting. After: Recruiting.